Akoya Biosciences, Inc. (AKYA)
Jul 8, 2025 - AKYA was delisted (reason: acquired by QTRX)
1.290
0.00 (0.00%)
Inactive · Last trade price on Jul 7, 2025
Akoya Biosciences Revenue
Akoya Biosciences had revenue of $16.64M in the quarter ending March 31, 2025, a decrease of -9.32%. This brings the company's revenue in the last twelve months to $79.96M, down -14.55% year-over-year. In the year 2024, Akoya Biosciences had annual revenue of $81.67M, down -15.48%.
Revenue (ttm)
$79.96M
Revenue Growth
-14.55%
P/S Ratio
0.80
Revenue / Employee
$390,054
Employees
205
Market Cap
64.34M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 81.67M | -14.96M | -15.48% |
Dec 31, 2023 | 96.63M | 21.77M | 29.09% |
Dec 31, 2022 | 74.86M | 19.94M | 36.31% |
Dec 31, 2021 | 54.92M | 12.47M | 29.39% |
Dec 31, 2020 | 42.44M | 207.00K | 0.49% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionAKYA News
- 4 months ago - AKOYA BIOSCIENCES INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akoya Biosciences, Inc. - AKYA - PRNewsWire
- 5 months ago - Kent Lake Responds to Quanterix's Post-Effective Amendment and Akoya's Superior $1.40-per-Share Alternative Proposal - PRNewsWire
- 5 months ago - Akoya Biosciences Reports First Quarter 2025 Financial Results - GlobeNewsWire
- 5 months ago - AKOYA BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akoya Biosciences, Inc. - AKYA - Business Wire
- 5 months ago - Kent Lake Issues Statement on Quanterix's Blatant Disregard for Will of Shareholders - Business Wire
- 5 months ago - Quanterix and Akoya Biosciences Announce Amended Merger Agreement - Business Wire
- 6 months ago - Akoya Biosciences and Enable Medicine Launch the Largest Commercially Available Single-Cell Spatial Proteomics Atlas - GlobeNewsWire
- 6 months ago - Akoya Biosciences Expands Biopharma Service Portfolio with New ADC Breast Cancer Assay and Real-world IO60 Insights at AACR 2025 - GlobeNewsWire